Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash & Current Investments data on file, last reported at $443.5 million in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 8.7% year-over-year to $443.5 million in Q2 2026; TTM through May 2026 was $443.5 million, a 8.7% decrease from a year earlier, with the FY2025 full-year figure at $592.9 million, down 2.73% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $443.5 million, down from $540.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for NRIX reached as high as $609.6 million in Q4 2024 and fell as low as $244.0 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $394.7 million across 5 years, with a median of $386.7 million in 2022.
• Across the five-year window, Cash & Current Investments retreated 24.86% in 2023 and soared 125.29% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $309.1 million in 2022, then slipped by 6.87% to $287.9 million in 2023, then jumped by 111.73% to $609.6 million in 2024, then dropped by 2.73% to $592.9 million in 2025, then slipped by 25.2% to $443.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $443.5 million in Q2 2026, $540.7 million in Q1 2026, and $592.9 million in Q4 2025.